Abstract
Radiobiological research over the past decades has provided evidence that cancer stem cell content and the intrinsic radiosensitivity of cancer stem cells varies between tumours, thereby affecting their radiocurability. Translation of this knowledge into predictive tests for the clinic has so far been hampered by the lack of methods to discriminate between stem cells and non-stem cells. New technologies allow isolation of cells expressing specific surface markers that are differentially expressed in tumour cell subpopulations that are enriched for cancer stem cells. Combining these techniques with functional radiobiological assays holds the potential to elucidate the role of cancer stem cells in radioresistance in individual tumours, and to use this knowledge for the development of predictive markers for optimization of radiotherapy.
Similar content being viewed by others
References
Clarke, M. F. et al. Cancer stem cells — perspectives on current status and future directions: AACR Workshop on Cancer Stem Cells. Cancer Res. 66, 9339–9344 (2006).
Dingli, D. & Michor, F. Successful therapy must eradicate cancer stem cells. Stem Cells 24, 2603–2610 (2006).
Baumann, M., Dubois, W. & Suit, H. D. Response of human squamous cell carcinoma xenografts of different sizes to irradiation: relationship of clonogenic cells, cellular radiation sensitivity in vivo, and tumor rescuing units. Radiation Res. 123, 325–330 (1990).
Kummermehr, J. & Trott, K. R. in Stem cells (ed. Potten, C. S.) 363–400 (Academic Press Limited, London, 1997).
Hill, R. P. & Milas, L. The proportion of stem cells in murine tumors. Int. J. Radiat. Oncol. Biol. Phys. 16, 513–518 (1989).
Trott, K. R. Tumour stem cells: the biological concept and its application in cancer treatment. Radiother. Oncol. 30, 1–5 (1994).
Al-Hajj, M., Wicha, M. S., Benito-Hernandez, A., Morrison, S. J. & Clarke, M. F. Prospective identification of tumorigenic breast cancer cells. Proc. Natl Acad. Sci. USA 100, 3983–3988 (2003).
O'Brien, C. A., Pollett, A., Gallinger, S. & Dick, J. E. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 445, 106–110 (2007).
Aoyama, H. et al. Hypofractionated stereotactic radiotherapy alone without whole-brain irradiation for patients with solitary and oligo brain metastasis using noninvasive fixation of the skull. Int. J. Radiat. Oncol. Biol. Phys. 56, 793–800 (2003).
Hof, H. et al. Stereotactic single-dose radiotherapy of stage I non-small-cell lung cancer (NSCLC). Int. J. Radiat. Oncol. Biol. Phys. 56, 335–341 (2003).
Onimaru, R. et al. Steep dose–response relationship for stage I non-small-cell lung cancer using hypofractionated high-dose irradiation by real-time tumor-tracking radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. (2007).
Onishi, H. et al. Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: updated results of 257 patients in a Japanese multi-institutional study. J. Thorac. Oncol. 2, S94–S100 (2007).
Madsen, B. L. et al. Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 Gy in five fractions for localized disease: first clinical trial results. Int. J. Radiat. Oncol. Biol. Phys. 67, 1099–1105 (2007).
Bernier, J., Hall, E. J. & Giaccia, A. Radiation oncology: a century of achievements. Nature Rev. Cancer 4, 737–747 (2004).
Thames, H. D. & Hendry, J. H. Fractionation in Radiotherapy (Taylor and Francis, Philadelphia, 1987).
Pusey, W. A. IX. The use of X-rays in carcinoma. Ann. Surg. 42, 910–917 (1905).
Walstam, R. in 1895-1995 Radiation Oncology, a Century of Progress and Achievements p17–46 (ESTRO, Leuven, 1995).
Holthusen, H. Erfahrungen über die Verträglichkeitsgrenze für Röntgenstrahlen und deren Nutzanwendung zur Verhütung von Schäden. Strahlenther. 57, 254–269 (1936) (in German).
Yaromina, A. et al. Pre-treatment number of clonogenic cells and their radiosensitivity are major determinants of local tumour control after fractionated irradiation. Radiother. Oncol. (2007).
Gerweck, L. E., Zaidi, S. T. & Zietman, A. Multivariate determinants of radiocurability. I: Prediction of single fraction tumor control doses. Int. J. Radiat. Oncol. Biol. Phys. 29, 57–66 (1994).
Taghian, A. et al. In vivo radiation sensitivity of glioblastoma multiforme. Int. J. Radiat. Oncol. Biol. Phys. 32, 99–104 (1995).
Suit, H. D. et al. Radiation response of xenografts of a human squamous cell carcinoma and a glioblastoma multiforme: a progress report. Int. J. Radiat. Oncol. Biol. Phys. 18, 365–373 (1990).
Yaromina, A. et al. Pimonidazole labelling and response to fractionated irradiation of five human squamous cell carcinoma (hSCC) lines in nude mice: The need for a multivariate approach in biomarker studies. Radiother. Oncol. 81, 122–129 (2006).
Schreiber, A. et al. Effect of the hypoxic cell sensitizer isometronidazole on local control of two human squamous cell carcinomas after fractionated irradiation. Strahlenther. Onkol. 180, 375–382 (2004).
Kaanders, J. H. et al. Pimonidazole binding and tumor vascularity predict for treatment outcome in head and neck cancer. Cancer Res. 62, 7066–7074 (2002).
Overgaard, J., Eriksen, J. G., Nordsmark, M., Alsner, J. & Horsman, M. R. Plasma osteopontin, hypoxia, and response to the hypoxia sensitiser nimorazole in radiotherapy of head and neck cancer: results from the DAHANCA 5 randomised double-blind placebo-controlled trial. Lancet Oncol. 6, 757–764 (2005).
Thames, H. D. Jr, Withers, H. R., Peters, L. J. & Fletcher, G. H. Changes in early and late radiation responses with altered dose fractionation: implications for dose–survival relationships. Int. J. Radiat. Oncol. Biol. Phys. 8, 219–226 (1982).
Petersen, C. et al. Repopulation of FaDu human squamous cell carcinoma during fractionated radiotherapy correlates with reoxygenation. Int. J. Radiat. Oncol. Biol. Phys. 51, 483–493 (2001).
Williams, M. V., Denekamp, J. & Fowler, J. F. A review of alpha/beta ratios for experimental tumors: implications for clinical studies of altered fractionation. Int. J. Radiat. Oncol. Biol. Phys. 11, 87–96 (1985).
Petersen, C. et al. Recovery from sublethal damage during fractionated irradiation of human FaDu SCC. Radiother. Oncol. 74, 331–336 (2005).
Beck-Bornholdt, H. P., Omniczynski, M., Theis, E., Vogler, H. & Wurschmidt, F. Influence of treatment time on the response of rat rhabdomyosarcoma R1H to fractionated irradiation. Acta Oncol. 30, 57–63 (1991).
Collins, A. T., Berry, P. A., Hyde, C., Stower, M. J. & Maitland, N. J. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res. 65, 10946–10951 (2005).
Singh, S. K. et al. Identification of human brain tumour initiating cells. Nature 432, 396–401 (2004).
Fang, D. et al. A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res. 65, 9328–9337 (2005).
Prince, M. E. et al. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc. Natl Acad. Sci. USA 104, 973–978 (2007).
Ricci-Vitiani, L. et al. Identification and expansion of human colon-cancer-initiating cells. Nature 445, 111–115 (2007).
Kelly, P. N., Dakic, A., Adams, J. M., Nutt, S. L. & Strasser, A. Tumor growth need not be driven by rare cancer stem cells. Science 317, 337 (2007).
Hill, R. P. Identifying cancer stem cells in solid tumors: case not proven. Cancer Res. 66, 1891–1895; discussion 1890 (2006).
Zheng, X., Shen, G., Yang, X. & Liu, W. Most C6 cells are cancer stem cells: evidence from clonal and population analyses. Cancer Res. 67, 3691–3697 (2007).
Calabrese, C. et al. A perivascular niche for brain tumor stem cells. Cancer Cell 11, 69–82 (2007).
Wang, J. et al. CD133 negative glioma cells form tumors in nude rats and give rise to CD133 positive cells. Int. J. Cancer 122, 761–768 (2008).
Jamieson, C. H. et al. Granulocyte–macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N. Engl. J. Med. 351, 657–667 (2004).
Maeda, S. et al. CD133 expression is correlated with lymph node metastasis and vascular endothelial growth factor-C expression in pancreatic cancer. Br. J. Cancer 98, 1389–1397 (2008).
Florek, M. et al. Prominin-1/CD133, a neural and hematopoietic stem cell marker, is expressed in adult human differentiated cells and certain types of kidney cancer. Cell Tissue Res. 319, 15–26 (2005).
Kennedy, J. A., Barabe, F., Poeppl, A. G., Wang, J. C. & Dick, J. E. Comment on “Tumor growth need not be driven by rare cancer stem cells”. Science 318, 1722; author reply 1722 (2007).
Barabe, F., Kennedy, J. A., Hope, K. J. & Dick, J. E. Modeling the initiation and progression of human acute leukemia in mice. Science 316, 600–604 (2007).
Hill, R. P. & Perris, R. “Destemming” cancer stem cells. J. Natl Cancer Inst. 99, 1435–1440 (2007).
Munro, T. R. & Gilbert, C. W. The relation between tumour lethal doses and the radiosensitivity of tumour cells. Br. J. Radiol. 34, 246–251 (1961).
Krause, M., Zips, D., Thames, H. D., Kummermehr, J. & Baumann, M. Preclinical evaluation of molecular-targeted anticancer agents for radiotherapy. Radiother. Oncol. 80, 112–122 (2006).
Hermans, A. F. & Barendsen, G. W. Changes of cell proliferation characteristics in a rat rhabdomyosarcoma before and after x-irradiation. Eur. J. Cancer 5, 173–189 (1969).
Hill, R. P., Bush, R. S. & Yeung, P. The effect of anaemia on the fraction of hypoxic cells in an experimental tumor. Br. J. Radiol. 44, 299–304 (1971).
Hewitt, H. B. & Wilson, C. W. Survival curves for tumor cells irradiated in vivo. Ann. NY Acad. Sci. 95, 818–827 (1961).
Stephens, T. C., Currie, G. A. & Peacock, J. H. Repopulation of γ-irradiated Lewis lung carcinoma by malignant cells and host macrophage progenitors. Br. J. Cancer 38, 573–582 (1978).
Suit, H., Shalek, R. & Wette, R. in Cellular Radiation Biology 514–530 (Williams and Wilkins, Baltimore, 1965).
Dubben, H. H., Thames, H. D. & Beck-Bornholdt, H. P. Tumor volume: a basic and specific response predictor in radiotherapy [see comments]. Radiother. Oncol. 47, 167–174 (1998).
Bentzen, S. M. & Thames, H. D. Tumor volume and local control probability: clinical data and radiobiological interpretations [comment]. Int. J. Radiat. Oncol. Biol. Phys. 36, 247–251 (1996).
Johnson, C. R., Thames, H. D., Huang, D. T. & Schmidt-Ullrich, R. K. The tumor volume and clonogen number relationship: tumor control predictions based upon tumor volume estimates derived from computed tomography. Int. J. Radiat. Oncol. Biol. Phys. 33, 281–287 (1995).
Malaise, E. P., Fertil, B., Chavaudra, N. & Guichard, M. Distribution of radiation sensitivities for human tumor cells of specific histological types: comparison of in vitro to in vivo data. Int. J. Radiat. Oncol. Biol. Phys. 12, 617–624 (1986).
Deacon, J., Peckham, M. J. & Steel, G. G. The radioresponsiveness of human tumours and the initial slope of the cell survival curve. Radiother. Oncol. 2, 317–323 (1984).
Buffa, F. M., Davidson, S. E., Hunter, R. D., Nahum, A. E. & West, C. M. Incorporating biologic measurements (SF(2), CFE) into a tumor control probability model increases their prognostic significance: a study in cervical carcinoma treated with radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 50, 1113–1122 (2001).
West, C. M., Davidson, S. E., Roberts, S. A. & Hunter, R. D. The independence of intrinsic radiosensitivity as a prognostic factor for patient response to radiotherapy of carcinoma of the cervix. Br. J. Cancer 76, 1184–1190 (1997).
Budach, W. et al. Tumors arising in SCID mice share enhanced radiation sensitivity of SCID normal tissues. Cancer Res. 52, 6292–6296 (1992).
Gerweck, L. E., Vijayappa, S., Kurimasa, A., Ogawa, K. & Chen, D. J. Tumor cell radiosensitivity is a major determinant of tumor response to radiation. Cancer Res. 66, 8352–8355 (2006).
Ogawa, K. et al. Influence of tumor cell and stroma sensitivity on tumor response to radiation. Cancer Res. 67, 4016–4021 (2007).
Kasten-Pisula, U. et al. The extreme radiosensitivity of the squamous cell carcinoma SKX is due to a defect in double-strand break repair. Radiother. Oncol. (in the press).
Withers, H. R. in Advances in radiation biology (eds. Lett, J. T. & Adler, H.) 241–247 (Academic Press, New York, 1975).
Steel, G. G., McMillan, T. J. & Peacock, J. H. The 5Rs of radiobiology. Int. J. Radiat. Biol. 56, 1045–8 (1989).
Beck-Bornholdt, H. P., Schmidt, R., Schwarz, R. C. & Hubener, K. H. Biological isoeffect distributions: consideration of the influence of dose per fraction and overall treatment time. A possible tool in future treatment planning. Strahlenther. Onkol. 167, 708–715 (1991).
Eramo, A. et al. Chemotherapy resistance of glioblastoma stem cells. Cell Death Differ. 13, 1238–1241 (2006).
Ghods, A. J. et al. Spheres isolated from 9L gliosarcoma rat cell line possess chemoresistant and aggressive cancer stem-like cells. Stem Cells 25, 1645–53 (2007).
Kang, M. K. & Kang, S. K. Tumorigenesis of chemotherapeutic drug-resistant cancer stem-like cells in brain glioma. Stem Cells Dev. 16, 837–847 (2007).
Liu, G. et al. Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol. Cancer 5, 67 (2006).
Ma, S., Lee, T. K., Zheng, B. J., Chan, K. W. & Guan, X. Y. CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway. Oncogene 27, 1749–1758 (2008).
Mimeault, M., Hauke, R., Mehta, P. P. & Batra, S. K. Recent advances in cancer stem/progenitor cell research: therapeutic implications for overcoming resistance to the most aggressive cancers. J. Cell. Mol. Med. 11, 981–1011 (2007).
Denekamp, J. Tumour stem cells: facts, interpretation and consequences. Radiother. Oncol. 30, 6–10 (1994).
Hendry, J. H., West, C. M., Moore, J. V. & Potten, C. S. Tumour stem cells: the relevance of predictive assays for tumour control after radiotherapy. Radiother. Oncol. 30, 11–16 (1994).
Lobrich, M. & Kiefer, J. Assessing the likelihood of severe side effects in radiotherapy. Int. J. Cancer 118, 2652–2656 (2006).
Akervall, J. Gene profiling in squamous cell carcinoma of the head and neck. Cancer Metastasis Rev. 24, 87–94 (2005).
Andreassen, C. N. Can risk of radiotherapy-induced normal tissue complications be predicted from genetic profiles? Acta Oncol. 44, 801–815 (2005).
Eriksen, J. G. et al. Molecular profiles as predictive marker for the effect of overall treatment time of radiotherapy in supraglottic larynx squamous cell carcinomas. Radiother. Oncol. 72, 275–282 (2004).
Buffa, F. M. et al. Molecular marker profiles predict locoregional control of head and neck squamous cell carcinoma in a randomized trial of continuous hyperfractionated accelerated radiotherapy. Clin. Cancer Res. 10, 3745–3754 (2004).
Bentzen, S. M. Theragnostic imaging for radiation oncology: dose-painting by numbers. Lancet Oncol. 6, 112–117 (2005).
Chao, K. S. et al. A novel approach to overcome hypoxic tumor resistance: Cu-ATSM-guided intensity-modulated radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 49, 1171–1182 (2001).
Nordsmark, M. et al. Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. Radiother. Oncol. (2005).
Kaanders, J. H. et al. Pimonidazole binding and tumor vascularity predict for treatment outcome in head and neck cancer. Cancer Res. 62, 7066–7074 (2002).
Eriksen, J. G., Alsner, J., Steiniche, T. & Overgaard, J. The possible role of TP53 mutation status in the treatment of squamous cell carcinomas of the head and neck (HNSCC) with radiotherapy with different overall treatment times. Radiother. Oncol. 76, 135–142 (2005).
Eriksen, J. G., Steiniche, T. & Overgaard, J. The influence of epidermal growth factor receptor and tumor differentiation on the response to accelerated radiotherapy of squamous cell carcinomas of the head and neck in the randomized DAHANCA 6 and 7 study. Radiother. Oncol. 74, 93–100 (2005).
Begg, A. C. et al. The value of pretreatment cell kinetic parameters as predictors for radiotherapy outcome in head and neck cancer: a multicenter analysis. Radiother. Oncol. 50, 13–23 (1999).
Lee, C. M. et al. Correlation between human epidermal growth factor receptor family (EGFR, HER2, HER3, HER4), phosphorylated Akt (P-Akt), and clinical outcomes after radiation therapy in carcinoma of the cervix. Gynecol. Oncol. 99, 415–421 (2005).
Eriksen, J. G. & Overgaard, J. Lack of prognostic and predictive value of CA IX in radiotherapy of squamous cell carcinoma of the head and neck with known modifiable hypoxia: an evaluation of the DAHANCA 5 study. Radiother. Oncol. 83, 383–388 (2007).
Hemmati, H. D. et al. Cancerous stem cells can arise from pediatric brain tumors. Proc. Natl Acad. Sci. USA 100, 15178–15183 (2003).
Bao, S. et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444, 756–760 (2006).
Bao, S. et al. Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res. 66, 7843–7848 (2006).
Rich, J. N. Cancer stem cells in radiation resistance. Cancer Res. 67, 8980–8984 (2007).
Blazek, E. R., Foutch, J. L. & Maki, G. Daoy medulloblastoma cells that express CD133 are radioresistant relative to CD133- cells, and the CD133+ sector is enlarged by hypoxia. Int. J. Radiat. Oncol. Biol. Phys. 67, 1–5 (2007).
Phillips, T. M., McBride, W. H. & Pajonk, F. The response of CD24−/low/CD44+ breast cancer-initiating cells to radiation. J. Natl Cancer Inst. 98, 1777–1785 (2006).
Woodward, W. A. et al. WNT/β-catenin mediates radiation resistance of mouse mammary progenitor cells. Proc. Natl Acad. Sci. USA 104, 618–623 (2007).
Chen, M. S. et al. Wnt/ β-catenin mediates radiation resistance of Sca1+ progenitors in an immortalized mammary gland cell line. J. Cell Sci. 120, 468–477 (2007).
Tannock, I. F. & Lee, C. Evidence against apoptosis as a major mechanism for reproductive cell death following treatment of cell lines with anti-cancer drugs. Br. J. Cancer 84, 100–105 (2001).
Brown, J. M. & Attardi, L. D. The role of apoptosis in cancer development and treatment response. Nature Rev. Cancer 5, 231–237 (2005).
Hambardzumyan, D., Squatrito, M. & Holland, E. C. Radiation resistance and stem-like cells in brain tumors. Cancer Cell 10, 454–456 (2006).
Ciampi, A., Kates, L., Buick, R., Kriukov, Y. & Till, J. E. Multi-type Galton–Watson process as a model for proliferating human tumour cell populations derived from stem cells: estimation of stem cell self-renewal probabilities in human ovarian carcinomas. Cell Tissue Kinet. 19, 129–140 (1986).
Diehn, M. & Clarke, M. F. Cancer stem cells and radiotherapy: new insights into tumor radioresistance. J. Natl Cancer Inst. 98, 1755–1757 (2006).
Wright, E. A. & Howard-Flanders, P. The influence of oxygen on the radiosensitivity of mammalian tissues. Acta Radiologica 48, 26–32 (1957).
Gray, L. H., Conger, A. D., Ebert, M., Hornsay, S. & Scott, O. C. A. The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br. J. Radiol. 26, 638–648 (1953).
Vaupel, P. & Mayer, A. Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev. 26, 225–239 (2007).
Overgaard, J. Hypoxic radiosensitization: adored and ignored. J. Clin. Oncol. 25, 4066–4074 (2007).
Hu, C. J., Wang, L. Y., Chodosh, L. A., Keith, B. & Simon, M. C. Differential roles of hypoxia-inducible factor 1α (HIF-1α) and HIF-2α in hypoxic gene regulation. Mol. Cell. Biol. 23, 9361–9374 (2003).
Covello, K. L. et al. HIF-2α regulates Oct-4: effects of hypoxia on stem cell function, embryonic development, and tumor growth. Genes Dev. 20, 557–570 (2006).
Gordan, J. D., Bertout, J. A., Hu, C. J., Diehl, J. A. & Simon, M. C. HIF-2α promotes hypoxic cell proliferation by enhancing c-myc transcriptional activity. Cancer Cell 11, 335–347 (2007).
Gustafsson, M. V. et al. Hypoxia requires notch signaling to maintain the undifferentiated cell state. Dev. Cell 9, 617–628 (2005).
Platet, N. et al. Influence of oxygen tension on CD133 phenotype in human glioma cell cultures. Cancer Lett. 258, 286–290 (2007).
Quennet, V. et al. Tumor lactate content predicts for response to fractionated irradiation of human squamous cell carcinomas in nude mice. Radiother. Oncol. 81, 130–135 (2006).
Ling, C. C. et al. Towards multidimensional radiotherapy (MD-CRT): biological imaging and biological conformality. Int. J. Radiat. Oncol. Biol. Phys. 47, 551–560 (2000).
Cordes, N., Seidler, J., Durzok, R., Geinitz, H. & Brakebusch, C. β1-integrin-mediated signaling essentially contributes to cell survival after radiation-induced genotoxic injury. Oncogene 25, 1378–1390 (2006).
Moore, K. A. & Lemischka, I. R. Stem cells and their niches. Science 311, 1880–1885 (2006).
Scadden, D. T. The stem-cell niche as an entity of action. Nature 441, 1075–1079 (2006).
Gilbertson, R. J. & Rich, J. N. Making a tumour's bed: glioblastoma stem cells and the vascular niche. Nature Rev. Cancer 7, 733–736 (2007).
Hambardzumyan, D. et al. PI3K pathway regulates survival of cancer stem cells residing in the perivascular niche following radiation in medulloblastoma in vivo. Genes Dev. 22, 436–48 (2008).
Bonner, J. A. et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 354, 567–578 (2006).
Pignon, J. P., Bourhis, J., Domenge, C. & Designe, L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet 355, 949–955 (2000).
Krause, M. et al. EGFR-TK inhibition before radiotherapy reduces tumour volume but does not improve local control: Differential response of cancer stem cells and nontumourigenic cells? Radiother. Oncol. 83, 316–325 (2007).
Baumann, M. et al. Selective inhibition of the epidermal growth factor tyrosine kinase by BIBX1382BS improves growth delay but not local control after fractionated irradiation in human FaDu squamous cell carcinoma in nude mice. Int. J. Radiat. Biol. 79, 1547–559 (2003).
Zips, D. et al. Experimental study on different combination schedules of VEGF-receptor inhibitor PTK787/ZK222584 and fractionated irradiation. Anticancer Res. 23, 3869–3876 (2003).
Zips, D. et al. Impact of adjuvant inhibition of vascular endothelial growth factor receptor tyrosine kinases on tumor growth delay and local tumor control after fractionated irradiation in human squamous cell carcinomas in nude mice. Int. J. Radiat. Oncol. Biol. Phys. 61, 908–914 (2005).
Weppler, S. A. et al. Response of U87 glioma xenografts treated with concurrent rapamycin and fractionated radiotherapy: Possible role for thrombosis. Radiother. Oncol. 82, 96–104 (2007).
Milas, L. et al. In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody. Clin. Cancer Res. 6, 701–708 (2000).
Nasu, S., Ang, K. K., Fan, Z. & Milas, L. C225 antiepidermal growth factor receptor antibody enhances tumor radiocurability. Int. J. Radiat. Oncol. Biol. Phys. 51, 474–477 (2001).
Krause, M. et al. Different classes of EGFR inhibitors may have different potential to improve local tumour control after fractionated irradiation: a study on C225 in FaDu hSCC. Radiother. Oncol. 74, 109–115 (2005).
Kozin, S. V. et al. Vascular endothelial growth factor receptor-2-blocking antibody potentiates radiation-induced long-term control of human tumor xenografts. Cancer Res. 61, 39–44 (2001).
Bayer, C. et al. PAI-1 levels predict response to fractionated irradiation in 10 human squamous cell carcinoma lines of the head and neck. Radiother. Oncol. 86, 361–368 (2008).
Schutze, C. et al. Effect of increase of radiation dose on local control relates to pre-treatment FDG uptake in FaDu tumours in nude mice. Radiother. Oncol. 83, 311–315 (2007).
Suit, H. D., Sedlacek, R. & Thames, H. D. in Rodent tumor models in experimental cancer therapy (ed. Kallman, R. F.) 138–148 (Pergamon Press, New York, 1987).
Acknowledgements
This work was supported in part by the Deutsche Forschungsgemeinschaft (Ba 1433) and by the National Cancer Institute of Canada with funds raised by the Tery Fox Run (15004). The authors wish to thank H.D. Thames, Houston, Texas, USA for helpful discussions.
Author information
Authors and Affiliations
Corresponding author
Related links
Related links
DATABASES
National Cancer Institute
FURTHER INFORMATION
Rights and permissions
About this article
Cite this article
Baumann, M., Krause, M. & Hill, R. Exploring the role of cancer stem cells in radioresistance. Nat Rev Cancer 8, 545–554 (2008). https://doi.org/10.1038/nrc2419
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrc2419
- Springer Nature Limited
This article is cited by
-
TMT-based quantitative proteomic analysis of spheroid cells of endometrial cancer possessing cancer stem cell properties
Stem Cell Research & Therapy (2023)
-
Regulation and signaling pathways in cancer stem cells: implications for targeted therapy for cancer
Molecular Cancer (2023)
-
Early stage evaluation of cancer stem cells using platinum nanoparticles/CD133+ enhanced nanobiocomposite
Cancer Nanotechnology (2023)
-
Harnessing progress in radiotherapy for global cancer control
Nature Cancer (2023)
-
The emerging role of the gut microbiome in cancer cell plasticity and therapeutic resistance
Cancer and Metastasis Reviews (2023)